SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE : To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS : With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax, target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONC LUS ION: Our results suggest that once-daily AMK for 4 weeks with a target max of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.
|Number of pages||7|
|Journal||International Journal of Tuberculosis and Lung Disease|
|Publication status||Published - 2017 Jul 1|
Bibliographical noteFunding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea, Seoul (NRF) funded by the Ministry of Science, information and communications technology, and Future Planning, Seoul (NRF- 2015R1A2A1A01003959) and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health Welfare, Seoul, Republic of Korea (HI15C2778).
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
- Infectious Diseases